Mattias SandstrÃ¶m

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5001900/publications.pdf

Version: 2024-02-01

34 papers	2,434 citations	257450 24 h-index	377865 34 g-index

34 all docs	34 docs citations	34 times ranked	2194 citing authors

#	Article	IF	Citations
1	Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing ¹⁷⁷Lu-DOTA-Octreotate Treatment. Journal of Nuclear Medicine, 2013, 54, 33-41.	5.0	216
2	First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the ¹¹¹In-ABY-025 Affibody Molecule. Journal of Nuclear Medicine, 2014, 55, 730-735.	5.0	211
3	Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [⁶⁸Ga]ABY-025 Affibody PET/CT. Theranostics, 2016, 6, 262-271.	10.0	204
4	Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using ¹⁷⁷Lu-DOTATATE. Journal of Nuclear Medicine, 2015, 56, 177-182.	5.0	179
5	Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 970-988.	6.4	179
6	Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 212-225.	6.4	152
7	Quantitative and Qualitative Intrapatient Comparison of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Net Uptake Rate for Accurate Quantification. Journal of Nuclear Medicine, 2014, 55, 204-210.	5.0	135
8	Comparative Biodistribution and Radiation Dosimetry of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2013, 54, 1755-1759.	5.0	123
9	Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ⁶⁸Ga-ABY-025 in Breast Cancer Patients. Journal of Nuclear Medicine, 2016, 57, 867-871.	5.0	88
10	Targeting of HER2-Expressing Tumors Using ¹¹¹In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. Journal of Nuclear Medicine, 2010, 51, 1131-1138.	5.0	81
11	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. EJNMMI Physics, 2017, 4, 27.	2.7	71
12	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. EJNMMI Physics, 2017, 4, 28.	2.7	65
13	Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE. Cancers, 2019, 11, 909.	3.7	56
14	ADAPT, a Novel Scaffold Protein-Based Probe for Radionuclide Imaging of Molecular Targets That Are Expressed in Disseminated Cancers. Cancer Research, 2015, 75, 4364-4371.	0.9	55
15	Minor changes in effective half-life during fractionated¹⁷⁷Lu-Octreotate therapy. Acta OncolÃ³gica, 2012, 51, 86-96.	1.8	54
16	Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. Theranostics, 2016, 6, 93-103.	10.0	53
17	Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1425-1431.	6.4	47
18	Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 531-539.	6.4	46

#	Article	IF	Citations
19	Phase I Study of ^{99m}Tc-ADAPT6, a Scaffold Proteinâ€“Based Probe for Visualization of HER2 Expression in Breast Cancer. Journal of Nuclear Medicine, 2021, 62, 493-499.	5.0	41
20	Method dependence, observer variability and kidney volumes in radiation dosimetry of 177Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Physics, 2015, 2, 24.	2.7	36
21	Optimal composition and position of histidine-containing tags improves biodistribution of 99mTc-labeled DARPin G3. Scientific Reports, 2019, 9, 9405.	3.3	34
22	¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors. Neuroendocrinology, 2020, 110, 662-670.	2.5	34
23	¹⁷⁷Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. Neuroendocrinology, 2021, 111, 330-343.	2.5	31
24	Comparative evaluation of 111In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors. Oncology Reports, 2015, 34, 1042-1048.	2.6	30
25	Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Physics, 2020, 7, 73.	2.7	27
26	Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. Cancers, 2021, 13, 962.	3.7	25
27	Lessons on Tumour Response: Imaging during Therapy with 177Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. Theranostics, 2012, 2, 459-471.	10.0	24
28	Kidney dosimetry during ¹⁷⁷Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance. Acta OncolÃ³gica, 2018, 57, 516-521.	1.8	24
29	¹⁸⁸Re-Z_{HER2:V2}, a Promising Affibody-Based Targeting Agent Against HER2-Expressing Tumors: Preclinical Assessment. Journal of Nuclear Medicine, 2014, 55, 1842-1848.	5.0	23
30	Parametric Net Influx Rate Images of ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE: Quantitative Accuracy and Improved Image Contrast. Journal of Nuclear Medicine, 2017, 58, 744-749.	5.0	23
31	Personalized radiation dosimetry for PRRTâ€”how many scans are really required?. EJNMMI Physics, 2020, 7, 26.	2.7	21
32	Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using ⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE. Journal of Nuclear Medicine, 2020, 61, 217-221.	5.0	20
33	In Vivo Instability of ¹⁷⁷Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 2020, 61, 1337-1340.	5.0	17
34	Performance of coincidence imaging with long-lived positron emitters as an alternative to dedicated PET and SPECT. Physics in Medicine and Biology, 2004, 49, 5419-5432.	3.0	9